BACKGROUND:Niclosamide. an FDA-approved anti-helminthic drug. has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading constitutively active androgen receptor splice variants (AR-Vs) or inhibiting other drug-resistance pathways (e. https://fitnessgravesyardes.shop/product-category/drive-set/